Skip to content
Peptigraph home

PT-141

Melanocortin agonist. PT-141 is FDA approved for HSDD (Vyleesi); research-chemical versions are not the approved drug.

Also called:VyleesiPT141
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusFDA approved for HSDD (Vyleesi)Not on the WADA Prohibited ListFull legal history

Key facts

How we verify
Class
Melanocortin agonist
Also called
Vyleesi, PT141
Vial sizes sold
10 mg
Community-reported sizes
Half-life
approximately 2.7 hours (range 1.9-4.0 h)
subcutaneous, in people · FDA label (Vyleesi)
FDA status
Approved for HSDD (Vyleesi)
Approved
WADA
Not listed
2026 Prohibited List
Everything on PT-141

PT-141 guides

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.Half-lifeWhat is measured, by route, and what is not.StoragePowder and mixed vials: temperature and shelf life.10 mg vialConcentration and unit tables for the 10 mg size.For libidoWhat research says about PT-141 for libido.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

PT-141: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Libido819Human RCT evidence, 4 of 4Journal of women's health 2022, PMID 35230162

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Compared with

PT-141vsKisspeptin-10Melanocortin agonist next to gnrh stimulator: evidence, dosing and legal status side by side.Not FDA approved · research chemicalRead the comparison →

Common stacks

PT-141 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

PT-141 + Kisspeptin-10

Common questions

Is PT-141 FDA approved?

PT-141 is FDA approved for HSDD (Vyleesi). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

Sources

  1. 1US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3United States: Approved by FDA as Vyleesi (bremelanotide), Cosette, original approval 21 June 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  4. 4FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  5. 5Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  6. 6These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.